(Arg)9

Modify Date: 2024-01-02 15:53:28

(Arg)9 Structure
(Arg)9 structure
Common Name (Arg)9
CAS Number 143413-47-2 Molecular Weight 1423.69000
Density N/A Boiling Point N/A
Molecular Formula C54H110N36O10 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of (Arg)9


(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide; exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

 Names

Name h-arg-arg-arg-arg-arg-arg-arg-arg-arg-oh
Synonym More Synonyms

 (Arg)9 Biological Activity

Description (Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide; exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.
Related Catalog
Target

IC50: 0.78 μM (neuroprotection)[1]

In Vitro Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
In Vivo (Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect[2]. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume[3].
Cell Assay (Arg)9 is prepared as 100× stocks (500 μM) in normal saline and assessed in a concentration range from 0.1 to 15 μM. (Arg)9 is added to culture 96-well plate 15 min prior to glutamic acid or kainic acid exposure. Neuronal viability is quantitatively using the MTS assay[1].
Animal Admin Rats: (Arg)9 (D-isoform) is prepared in 100× stocks (500 μM in water and assessed in a concentration range from 0.1 to 20 μM. Rats are fasted overnight and subjected to filament permanent middle cerebral artery occlusion (MCAO). Thirty minutes post-MCAO rats are intravenously treated with (Arg)9 (1 μmol/kg in 600 μL over 5 minutes) or vehicle (normal saline for injection; 600 μL over 5 minutes). Treatments are randomized and all procedures are performed masked to treatment. Twenty-four hours post-MCAO infarct area assessment is performed[2].
References

[1]. Meloni BP, et al. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014 Mar;34(2):173-81.

[2]. Meloni BP, et al. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab. 2015 Jun;35(6):993-1004.

[3]. Milani D, et al. Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat strokemodel. BMC Neurosci. 2016 May 3;17(1):19.

 Chemical & Physical Properties

Molecular Formula C54H110N36O10
Molecular Weight 1423.69000
Exact Mass 1422.92000
PSA 853.22000
LogP 3.19200

 Synonyms

(ARG)9
nona-L-arginine
Nonaarginine
H(-Arg)9-OH,Nonaarginine
(Arg)9 peptide
RRRRRRRRR
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg